Quantification of Steroid Receptors Gene Expression in Breast Cancer Patients: Possible Correlation with Serum Level of Adipocytokines

Esfahlan, Rana Jahanban; Zarghami, Nosratollah; Rahmati-Yamchi, Μohammad; Amir, Mohammad; Valiyari, Samira; Jahanban-Esfahlan, Ali; Jozani, Raziallah Jafari; Gojazadeh, Morteza; Mamaghani, Fereidoun; Mobasseri, Majid

doi:10.4236/jct.2011.25088

Cited by 12 publications

(4 citation statements)

References 25 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like as Dieudonne, they demonstrate that E2 significantly reduces the AdipoR1 (adiponectin receptor) expression in ERα-positive MCF-7 breast can- Studies show that ERβ is dominant ER in normal breast and so ER signaling is normal is cases with normal serum level of adiponectin. B: At the other hand, obese cases frequently represent decreased serum level of this adipocytokine and display a higher expression of ERα mRNA as we observed in our study [11], from previous studies we know that mitogenic effects attributed to over expression of ERα and this receptor is the dominant ER in cancerous breast where the ratio of ERα/ERβ increases and disrupt normal ER signaling.…”

Section: Discussionsupporting

confidence: 58%

“…According to the results of our previous works [10,11] and the findings of this study we propose that affecting the estrogen receptor status is another mechanism of action of adiponectin that can affect prognosis of disease in breast cancer patients (see Figure 3). Far now many studied focused on antiproliferative and apoptotic effects of adiopnection on different breast cancer cell lines (16 -18) (see Table 1).…”

Section: Discussionmentioning

confidence: 99%

“…Many in vitro studies revealed the anti-tumoral effects of this adipocytokine such as its anti-angiogenic, pro apoptotic, anti inflammatory and anti prolifrative activities that propose it as a potent tumor suppressor gene [16,17]. Recently it is proposed that there may be a crosstalk between this adipokine and estrogen receptor signaling [11,17], so the aim of this study was to determine the possible connection between serum level of adiponectin and ERα and ERβ gene expression in breast cancer tissues.…”

Section: Introductionmentioning

confidence: 99%

“…ERα has mitogennic properties and cause to proliferation of mammary cells, while ERβ exerts anti proliferative activities and can oppose and regulate ERα gene expression [7][8][9]. In normal breast ERβ is the dominant estrogen receptor while, in cancerous breast the ratio of ERα/ERβ increases and the expression of ERα gene is dominant [10,11]. Apart from role of estrogen and its receptors in pathogenesis of breast cancer, it is now recognized that the white adipose tissue (WAT) produces a variety of bioactive peptides, collectively termed "adipokines" [12,13].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Adiponectin Can Affect ER Signaling in Obese Breast Cancer Patients

Esfahlan¹,

Zarghami²,

Valiyari³

et al. 2012

JCT

Self Cite

View full text Add to dashboard Cite

Background: While the various antitumororal activities of adiponectin as an adipocyte-derived hormone well studied, it is speculated that there is a crosstalk between adiponectin and esterogen receptor (ER) signaling. To test this hypothesis we evaluate the possible correlation between serum level of adiponectin with two estrogen receptors (ERα and ERβ) gene expression in breast cancer patients. Methods: In this case-control study, 70 women with breast cancer participated with different grades of obesity (36 none obese, BMI < 25 kg/m 2 and 34 obese, BMI ≥ 25 kg/m 2 ).The mean age of Participants was 44.53 yr ± 1.79 yr (21 yr -70 yr) .Serum level of adiponectin determined by ELISA. Following quantitative expression of estrogen receptors mRNA in tumor tissues was evaluated by Real-time PCR. Results: We find a significant reverse correlation between serum level of Adiponectin and ERα mRNA (r = -0.229, n = 64, p = 0.035) but no correlation was between adiponectin and ERβ in samples (p = 0.228). The lower adiponectin multiplied the odds of having higher ERα mRNA level by a factor of OR = 4.33, 1.28 -14.6, 95% confidence interval (CI) as compared with those that displayed a moderate or higher serum level of adiponectin (>7.02 ng/ml). The same odds for next estrogen receptor, ERβ, was not greater than unity (OR = 0.31, 0.06 -1.56, 95% CI). Conclusion: According to the obtained results, it is speculated that as adiponectin can affect ERs gene expression, so affecting the steroid receptor signaling can be proposed as a new underling mechanism of action for this adipokine in breast cancer pathogenesis especially in obese ones.

show abstract

Section: Discussionsupporting

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Adiponectin Can Affect ER Signaling in Obese Breast Cancer Patients

Esfahlan¹,

Zarghami²,

Valiyari³

et al. 2012

JCT

Self Cite

View full text Add to dashboard Cite

show abstract

Implications of resistin in type 2 diabetes mellitus and coronary artery disease: Impairing insulin function and inducing pro‐inflammatory cytokines

Emamalipour

Seidi

Jahanban-Esfahlan

2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Diabetes mellitus is a metabolic and chronic disorder, which is very common all over the world. Many genetic and nongenetic factors are involved in the development of type 2 diabetes mellitus (T2DM). Meanwhile, the resistin gene is an important candidate in the pathogenesis of this complex condition. High levels of transcription of the resistin gene are associated with inflammation, insulin resistance, initiation and development of T2DM and atherosclerosis progression through induction of secretion of bioactive materials from adipocytes. Releasing adipose tissue-derived inflammatory cytokines is associated with inflammatory processes activation, which causes inhibition of insulin action via interference with insulin signaling, such that these disorders can contribute to insulin resistance. With the direct effect of resistin and other inflammatory mediators on vascular endothelial cells and arterial walls, the expression of cell adhesion molecules is increased. This process can lead to atherosclerosis and will result in coronary artery disease (CAD). In this review, we will explore the effects of resistin on inflammation and insulin resistance that may lead to type 2 diabetes and CAD. K E Y W O R D Satherosclerosis, coronary artery disease, inflammation, insulin, resistin, type 2 diabetes mellitus

show abstract

Novel DOX-MTX Nanoparticles Improve Oral SCC Clinical Outcome by Down Regulation of Lymph Dissemination Factor VEGF-C Expression in vivo: Oral and IV Modalities

Abbasi

Amir²,

Hamishehkar³

et al. 2014

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

Background: Oral squamous cell carcinoma (OSCC) remains as one of the most difficult malignancies to control because of its high propensity for local invasion and cervical lymph node dissemination. The aim of present study was to evaluate the efficacy of novel pH and temperature sensitive doxorubicin-methotrexateloaded nanoparticles (DOX-MTX NP) in terms of their potential to change the VEGF-C expression profile in a rat OSCC model. Materials and Methods: 120 male rats were divided into 8 groups of 15 animals administrated with 4-nitroquinoline-1-oxide to induce OSCCs. Newly formulated doxorubicin-methotrexate-loaded nanoparticles (DOX-MTX NP) and free doxorubicin were IV and orally administered. Results: Results indicated that both oral and IV forms of DOX-MTX-nanoparticle complexes caused significant decrease in the mRNA level of VEGF-C compared to untreated cancerous rats (p<0.05) . Surprisingly, the VEGF-C mRNA was not affected by free DOX in both IV and oral modalities (p>0.05). Furthermore, in DOX-MTX NP treated group, less tumors characterized with advanced stage and VEGF-C mRNA level paralleled with improved clinical outcome (p<0.05). In addition, compared to untreated healthy rats , the VEGF-C expression was not affected in healthy groups that were treated with IV and oral dosages of nanodrug (p>0.05). Conclusions: VEGF-C is one of the main prognosticators for lymph node metastasis in OSCC. Down-regulation of this lymph-angiogenesis promoting factor is a new feature acquired in group treated with dual action DOX-MTX-NPs. Beside the synergic apoptotic properties of concomitant use of DOX and MTX on OSCC, DOX-MTX NPs possessed anti-angiogenesis properties which was related to the improved clinical outcome in treated rats. Taking together, we conclude that our multifunctional doxorubicin-methotrexate complex exerts specific potent apoptotic and anti-angiogenesis properties that could ameliorate the clinical outcome presumably via down-regulating dissemination factor-VEGF-C expression in a rat OSCC model.

show abstract

Quantification of Steroid Receptors Gene Expression in Breast Cancer Patients: Possible Correlation with Serum Level of Adipocytokines

Abstract: Background: While the role of adipocyte-derived hormones in breast cancer pathogenesis well studied, it is speculated that there is a crosstalk between adipocytokines and Esterogen receptor

Cited by 12 publications

References 25 publications

Adiponectin Can Affect ER Signaling in Obese Breast Cancer Patients

Adiponectin Can Affect ER Signaling in Obese Breast Cancer Patients

Implications of resistin in type 2 diabetes mellitus and coronary artery disease: Impairing insulin function and inducing pro‐inflammatory cytokines

Novel DOX-MTX Nanoparticles Improve Oral SCC Clinical Outcome by Down Regulation of Lymph Dissemination Factor VEGF-C Expression in vivo: Oral and IV Modalities

Contact Info

Product

Resources

About